H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bausch Health Companies (NYSE:BHC) Inc on Tuesday, setting a price target of $55, which is approximately 62.72% above the present share price of $33.8.
Selvaraju expects Bausch Health Companies Inc to post earnings per share (EPS) of -$0.43 for the first quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Bausch Health Companies, with an average price target of $35.17.
The analysts price targets range from a high of $55 to a low of $22.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $2.21 billion and a net profit of $431 million. The company's market cap is $12.02 billion.
According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 34.9% and a 66.30% success rate.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.